Patents Assigned to SAB, LLC
  • Publication number: 20240279315
    Abstract: Provided are human polyclonal immunoglobulin products specific for influenza hemagglutinin (HA) protein for use in treating or preventing disease associated with an influenza infection. Further provided herein are methods for making such human polyclonal immunoglobulins in a transgenic ungulate, such as, but not limited to, using a transchromosomic bovine (TcB) system.
    Type: Application
    Filed: February 16, 2024
    Publication date: August 22, 2024
    Applicant: SAB, LLC
    Inventors: Eddie J. SULLIVAN, Hua WU, Christoph L. BAUSCH, Thomas LUKE
  • Publication number: 20240010734
    Abstract: Provided are human polyclonal immunoglobulin products specific for Epidermal Growth Factor Receptor (EGFR) for use in treating or preventing cancer. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.
    Type: Application
    Filed: November 12, 2021
    Publication date: January 11, 2024
    Applicant: SAB, LLC
    Inventors: Hua WU, Eddie J. SULLIVAN, Kristi A. Egland, Christoph L. BAUSCH
  • Publication number: 20230406934
    Abstract: Provided are human polyclonal immunoglobulin products specific for Programmed Death-Ligand 1 (PD-L1) for use in treating or preventing cancer. Further provided are methods for making such compositions in a transgenic ungulate, e.g. using a transchromosomic bovine (TcB) system.
    Type: Application
    Filed: November 12, 2021
    Publication date: December 21, 2023
    Applicant: SAB, LLC
    Inventors: Christoph L. BAUSCH, Hua Wu, Kristi A. EGLAND, Eddie J. SULLIVAN
  • Patent number: 11072649
    Abstract: Disclosed herein is a method for producing human antibodies against a pathogen comprising injecting a non-human animal with a pathogen-derived DNA vaccine in at least two locations of the animal; injecting the animal with an adjuvant in a location of the animal different from the location of the DNA vaccine location; collecting plasma from the animal after the injections; and purifying polyclonal antibody from the plasma.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: July 27, 2021
    Assignee: SAB, LLC
    Inventors: Jay Hooper, Eddie Sullivan, Hua Wu
  • Patent number: 9902970
    Abstract: The invention relates to large-scale production of human antibodies by transgenic animals with high production of fully human IgG up to >10 g/L in sera with human IgG1 subclass dominancy. This invention also supports a feasibility of complex chromosome engineering for complicated genetic studies in non-murine mammalian species.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: February 27, 2018
    Assignee: SAB, LLC
    Inventors: Yoshimi Kuroiwa, Hiroaki Matsushita, Akiko Sano
  • Patent number: 9775332
    Abstract: A human artificial chromosome vector comprising a gene encoding a human antibody heavy chain, a gene encoding a human antibody light chain, and a gene encoding an IgM heavy chain constant region derived from a nonhuman animal.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: October 3, 2017
    Assignee: SAB, LLC
    Inventors: Yoshimi Kuroiwa, Hiroaki Matsushita, Akiko Kanai
  • Patent number: 9315824
    Abstract: The present invention provides a human artificial chromosome vector comprising a gene encoding the human antibody heavy chain, a gene encoding the human antibody light chain, and a gene encoding IgM heavy chain constant region derived from a nonhuman animal; and being capable of producing a human antibody with a higher efficiency when the vector is introduced into an animal. By immunizing the animal produced using a human artificial chromosome vector of the present invention with a desired antigen, a large quantity of human polyclonal antibodies can be supplied.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: April 19, 2016
    Assignee: SAB, LLC
    Inventors: Yoshimi Kuroiwa, Hiroaki Matsushita, Akiko Sano